Found: 5
Select item for more details and to access through your institution.
124-LB: Development of IDG-16177, a Selective and Safe GPR40 Agonist for the Treatment of Type 2 Diabetes.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-124-LB
- By:
- Publication type:
- Article
123-LB: IDG-16177, a Potent, Orally-Bioavailable GPR40 Agonist, Improves Glycemic Control and Glucose-Stimulated Insulin Secretion in Preclinical Studies.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-123-LB
- By:
- Publication type:
- Article
122-LB: In Vitro Pharmacodynamic Studies of IDG-16177, a Potent GPR40 Agonist, for the Treatment of Type 2 Diabetes.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-122-LB
- By:
- Publication type:
- Article
VRK3-mediated nuclear localization of HSP70 prevents glutamate excitotoxicity-induced apoptosis and Aβ accumulation via enhancement of ERK phosphatase VHR activity.
- Published in:
- Scientific Reports, 2016, p. 38452, doi. 10.1038/srep38452
- By:
- Publication type:
- Article
Stress-induced nuclear translocation of CDK5 suppresses neuronal death by downregulating ERK activation via VRK3 phosphorylation.
- Published in:
- Scientific Reports, 2016, p. 28634, doi. 10.1038/srep28634
- By:
- Publication type:
- Article